K4 Elite
K4 Elite
A long-acting acylated analog of glucagon-like peptide-1 (GLP-1) studied for its effects on glucose homeostasis, appetite signaling, and body-weight regulation in laboratory and clinical research.
Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1) engineered for prolonged receptor engagement. It shares roughly 97% sequence homology with native GLP-1 and carries a single amino-acid substitution (Arg34) together with a C16 palmitic-acid chain attached through a glutamic-acid spacer at Lys26. These modifications promote reversible binding to albumin, which slows enzymatic degradation and renal clearance in study models.
In the published literature liraglutide is examined as a reference incretin-mimetic peptide. Researchers use it to probe how sustained GLP-1 receptor activation influences insulin secretion, glucagon suppression, gastric emptying, and central appetite pathways. It has been evaluated in a large body of preclinical and clinical trials.
This entry summarizes the scientific literature for reference purposes only and describes findings reported by investigators rather than outcomes for any individual.
Liraglutide is an agonist at the GLP-1 receptor, a class-B G-protein-coupled receptor expressed in pancreatic islet cells and in regions of the central nervous system. Receptor activation raises intracellular cyclic AMP, which in study systems potentiates glucose-dependent insulin release from beta cells while attenuating glucagon output from alpha cells.
The albumin-binding fatty-acid moiety extends the peptide's half-life relative to native GLP-1, giving a longer duration of receptor signaling in reported pharmacokinetic studies. Investigators have also described activation of GLP-1 receptors in hypothalamic and brainstem circuits associated with satiety signaling and slowed gastric emptying.
The LEADER trial (Marso et al., NEJM 2016) was a large randomized, double-blind, placebo-controlled cardiovascular outcomes study in adults with type 2 diabetes, reporting a lower rate of composite cardiovascular events in the liraglutide arm over a median 3.8-year follow-up. This is reported here strictly as a summary of published human research.
The SCALE program (Pi-Sunyer et al., NEJM 2015) evaluated liraglutide against placebo in participants with overweight or obesity, reporting greater mean body-weight reduction in the active arm. Investigators documented gastrointestinal effects as the most common tolerability finding.
Preclinical work by Knudsen and colleagues characterized the acylation chemistry and albumin-binding kinetics that underlie the peptide's extended pharmacokinetic profile in animal and in-vitro systems.
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.